# US 2023/0321070 A1 · Co-crystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0321070 A1
- Document ID: US20230321070A1
- Status: Published application
- Kind: A1
- Application number: 18/210,217
- Filed: 2023-06-15
- Published: 2023-10-12
- Earliest claimed: 2021-08-31
- Assignees: CereSpir Incorporated
- Applicants: CereSpir Incorporated
- Inventors: Daniel G. Chain; Ronald Mueller
- Web page: https://patentgrep.com/patent/US20230321070A1

## CPC

- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- C07C 61/40: containing halogen
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07C 2601/02: with a three-membered ring
- C07D 213/79: Acids; Esters
- C07D 213/80: in position 3
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containg the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.

## Claims

### Claim 1

A method of treating a neurodegenerative condition in a human, comprising administering a therapeutically effective dosage regimen of a co-crystal comprising itanapraced and a coformer selected from a group consisting of a group consisting of nicotinamide, picolinamide, isonicotinamide, isonicotinic acid, and nicotinic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative condition is selected from a group consisting of Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, juvenile neuronal ceroid lipofuscinosis, age-related macular degeneration, dementias, neurological infection, neurologic injury, neurologic inflammation and tauopathies.

### Claim 3 (depends on 2)

The method of claim 2, wherein the coformer is nicotinamide.

### Claim 4 (depends on 3)

The method of claim 3, wherein a stoichiometric ratio of itanapraced to nicotinamide is from about 0:8:1.2 to about 1.2:0.8.

### Claim 5 (depends on 4)

The method of claim 4, wherein the co-crystal has an X-ray Powder Diffraction Pattern (XRPD) with specific peaks, expressed in 2Θ produced from a Cu radiation source (λ=1.54 Å after Ni filtering), at about 14.63°; 14.90°; 15.56°; 16.71°; 18.24°; 18.46°; 20.030; 20.270; 22.010; 22.270; 24.170; 24.470; 26.140; 26.470; 27.830; 28.850; 29.97°; 30.64°; 32.42°; 34.07°; and 39.14°, all +/−0.2 degrees 2Θ.

### Claim 6 (depends on 5)

The method of claim 5, wherein the neurodegenerative condition is a tauopathy selected from a group consisting of Amyotrophic Lateral Sclerosis, Pick's disease, Frontal Temporal Dementia and Progressive Supranuclear Palsy.

### Claim 7 (depends on 2)

The method of claim 2, wherein the neurologic injury is Traumatic Brain Injury.

### Claim 8 (depends on 5)

The method of claim 5, wherein the X-ray Powder Diffraction Pattern (XRPD) is substantially the same as the X-ray Powder Diffraction Pattern (XRPD) shown in FIG. 3A.

### Claim 9 (depends on 1)

The method of claim 1, wherein the co-crystal is administered orally.

### Claim 10 (depends on 9)

The method of claim 9, wherein the co-crystal is administered in a solid dosage form.

### Claim 11 (depends on 10)

The method of claim 10, wherein the solid dosage form is a tablet.

### Claim 12 (depends on 10)

The method of claim 10, wherein the solid dosage form is formulated as an immediate release formulation.

### Claim 13 (depends on 9)

The method of claim 9, wherein the co-crystal is administered at a dose from about 3 mg/day to about 3000 mg/day.

### Claim 14 (depends on 13)

The method of claim 13, wherein the dose is from about 5 mg/day to about 2000 mg/day.

### Claim 15 (depends on 1)

The method of claim 1, wherein the co-crystal is administered from 1 to 4 times per day.

### Claim 16

A method of treating oxidative stress in a human, comprising administering a therapeutically effective dosage regimen of a co-crystal comprising itanapraced and a coformer selected from a group consisting of a group consisting of nicotinamide, picolinamide, isonicotinamide, isonicotinic acid, and nicotinic acid.

### Claim 17

A method of treating a neurodegenerative condition in a human, comprising administering a therapeutically effective dosage regimen of a co-crystal comprising a praced and a coformer comprising nicotinamide.

### Claim 18 (depends on 17)

The method of claim 17, wherein the praced and the coformer are in a crystal lattice.

### Claim 19 (depends on 19)

The method of claim 19, wherein the praced is itanapraced.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cocrystal is less hygroscopic than itanapraced.
